Revision: June 18, 2018, 8 a.m.
CHAPTER 263
SB 581-FN - FINAL VERSION
03/14/2018 0976s
2May2018... 1718h
2018 SESSION
18-2755
01/03
SENATE BILL 581-FN
SPONSORS: Sen. Sanborn, Dist 9
COMMITTEE: Health and Human Services
─────────────────────────────────────────────────────────────────
AMENDED ANALYSIS
This bill amends the definition of compounding for the purposes of the law regulating pharmacists and pharmacies. This bill also establishes a study committee to study rulemaking authority for reconstituted drugs.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
03/14/2018 0976s
2May2018... 1718h 18-2755
01/03
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Eighteen
Be it Enacted by the Senate and House of Representatives in General Court convened:
263:1 Pharmacists and Pharmacies; Definitions. Amend RSA 318:1, III-a to read as follows:
III-a. "Compounding'' means the preparation, mixing, assembling, packaging or labeling of a drug or device as a result of a practitioner's prescription drug order or initiative based on the pharmacist-patient-prescriber relationship in the course of professional practice or, for the purpose of, or as an incident, to research, teaching, or chemical analysis, but not selling or dispensing. "Compounding'' also includes the preparation of drugs or devices in anticipation of prescription drug orders based on routine, regularly observed prescribing patterns. "Compounding'' shall not include the reconstitution of powdered formulations before dispensing or the addition of flavoring. "Compounding" shall not include the simple addition of flavoring, nor shall it include the preparation of a single dose of a nonhazardous commercially available drug or licensed biologic for administration within 2 hours of preparation to an individual patient when done in accordance with the manufacturer's approved labeling or instructions consistent with that labeling.
263:2 Committee Established. There is established a committee to study rulemaking authority for reconstituted drugs.
263:3 Membership and Compensation.
I. The members of the committee shall be as follows:
(a) Three members of the house of representatives, at least 2 of whom shall be from the house executive departments and administration committee, appointed by the speaker of the house of representatives.
(b) One member of the senate, appointed by the president of the senate.
II. Members of the committee shall receive mileage at the legislative rate when attending to the duties of the committee.
263:4 Duties. The committee shall study rulemaking authority for reconstituted drugs. The committee shall solicit information and testimony from any individual or entity the committee deems relevant to its study.
263:5 Chairperson; Quorum. The members of the study committee shall elect a chairperson from among the members. The first meeting of the committee shall be called by the first-named house member. The first meeting of the committee shall be held within 45 days of the effective date of this section. Three members of the committee shall constitute a quorum.
263:6 Report. The committee shall report its findings and any recommendations for proposed legislation to the speaker of the house of representatives, the president of the senate, the house clerk, the senate clerk, the governor, and the state library on or before November 1, 2018.
263:7 Effective Date. This act shall take effect upon its passage.
Approved: June 12, 2018
Effective Date: June 12, 2018